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ABSTRACT Parkinson disease is characterized by a major
loss (z8O% or more) of dopaminergic nigrostriatal neurons
and by an increased turnover of neurotransmitter by surviving
neurons ofthe nigrostriatal tract. In theory, increased turnover
of dopamine should be associated with an oxidative stress
derived from increased production of hydrogen peroxide. The
peroxide is formed during the oxidative deamination of dopa-
mine by monoamine oxidase. In experiments with mice, in-
creased presynaptic turnover of dopamine was evoked by
injection of reserpine, which interferes with the storage of
dopamine in synaptic vesicles. Loss of dopamine and formation
of deaminated metabolites were accompanied by a significant
rise (87.8%) in the level of oxidized glutathione in brain. This
change was observed in the striatum, which is richly innervated
by dopamine terminals, but not in the frontal cortex, which
receives a much sparser innervation by catecholamine nerve
terminals. The rise in oxidized glutathione was seen even
though dopamine terminals constitute only 1% or less of the
mass of the striatum. Clorgyline, an inhibitor of monoamine
oxidase type A, blocked the formation of oxidized glutathione.
These observations confirm that a selective increase in neuro-
transmitter turnover within nigrostriatal nerve terminals can
evoke a change in cellular redox status. We suggest that an
oxidative stress may play a role in the natural history of
Parkinson disease.
GSH peroxidaseH2O2 +2GSH > GSSG +2H20 [2]
GSSG reductase
GSSG + NADPH + H+ - d 2 GSH + NADP+ [3]
Normally, GSSG is efficiently reduced by glutathione reduc-
tase (reduced NADP:oxidized-glutathione oxidoreductase,
EC 1.6.4.2) and, as a consequence, levels of GSSG in various
tissues, including brain (6), constitute only 1% or less of the
total glutathione (GSH + GSSG). Levels of GSSG can rise,
however, during exposure of tissues to added peroxides or
peroxide-generating cell toxins (7-9). The ratio of oxidized to
reduced glutathione reflects, in part, the redox state of the
tissue.
To evoke increased presynaptic turnover of dopamine, we
used the drug reserpine. Reserpine prevents the storage of
dopamine in neuronal transmitter vesicles by interfering with
the transport of dopamine from the cytosol into the vesicles
(10). As a result, the metabolism of dopamine by mitochon-
drial MAO is accelerated. The net effect is the disappearance
of dopamine and the simultaneous formation of acidic metab-
olites (11, 12). This action mimics increased neuronal activ-
ity, where increased release and reuptake of transmitter leads
to increased presynaptic oxidation of dopamine. We assessed
the effect of reserpine on the redox status of dopaminergic
nerve terminals in the striatum by measuring changes in the
levels of GSSG.
The factors responsible for loss or dysfunction of nigrostriatal
dopamine neurons in Parkinson disease are not understood.
It is well established by neurochemical assay at autopsy (1)
and in animals with partial lesions of the nigrostriatal tract (2,
3) that surviving dopamine neurons are characterized by
increased turnover of neurotransmitter, an apparent com-
pensatory response to the loss of neurons. Because the
turnover of dopamine by monoamine oxidase [MAO; mon-
oamine:oxygen oxidoreductase (deaminating), EC 1.4.3.4] is
associated with the formation of a cellular oxidant, namely,
hydrogen peroxide, increased neuronal activity could, in
theory, be associated with an oxidative stress. In other
systems, increased generation of H202 results in either tissue
damage or overt cellular destruction. We report here that
increased presynaptic metabolism of neurotransmitter alters
the redox state of dopamine nerve terminals in the striatum.
The H202 that is generated by MAO (a mitochondrial
enzyme) is scavenged by glutathione (GSH) peroxidase
(reduced-glutathione: hydrogen-peroxide oxidoreductase,
EC 1.11.1.9) (4, 5), leading to the formation of glutathione
disulfide (GSSG).
MAO
dopamine + 02 + H20 - > H202 + NH3 +
3,4-dihydroxyphenylacetaldehyde [1]
MATERIALS AND METHODS
Reserpine (Serpasil; CIBA Pharmaceutical) was dissolved in
20 ,u1 of glacial acetic acid and diluted into 0.3 mM dextrose
in distilled water. Clorgyline (May & Baker, Dagenham,
England) was prepared in isotonic saline.
Male Swiss-Webster mice (25-30 g; Ace Breeders, Boyer-
town, PA) received intraperitoneal injections of reserpine (10
mg/kg); control mice received the injection vehicle alone.
Where indicated, mice received the MAO inhibitor, clorgy-
line (2.5 mg/kg, i.p.) 18 hr prior to injection of reserpine. Two
hours after reserpine, the mice were rapidly decapitated, the
striatum and frontal cortex were dissected over ice, and
tissues were homogenized in 10 vol of cold 0.4 M perchloric
acid containing 0.1 mM diethylenetriaminepentaacetic acid (a
metal chelator).
Spectrophotometric assays for GSSG were carried out
with a modification (6) of the enzymatic recycling procedure
of Teitze (13), which is based on the activity of GSSG
reductase. GSH was first removed (7) by reaction with
N-ethylmaleimide, followed by removal of the N-ethylmale-
imide by chromatography over Sep-Pak C18 cartridges
(Millipore/Waters). After the addition of 0.4 mM 5,5'-
dithiobis(2-nitrobenzoic acid), 0.17 mM NADPH, and GSSG
Abbreviations: MAO, monoamine oxidase; GSSG, oxidized glu-
tathione; GSH, reduced glutathione.
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Table 1. Effect of reserpine on GSSG levels in striata of mice, with and without pretreatment with clorgyline
Striatal GSSG, tLM Rise in GSSG, puM
Control Reserpine Reserpine/clorgyline Reserpine Reserpine/clorgyline
Exp. (A) (B) (C) (B - A) (C - A)
1 5.1 ± 0.4 10.4 ± 0.2 4.9 ± 0.3* 5.3 -0.2
2 6.1 ± 0.6 12.4 ± 0.1 6.7 ± 0.0* 6.3 0.6
3 6.4 ± 0.3 11.2 ± 0.3 7.5 ± 0.0* 4.8 1.1
4 12.8 ± 0.2 17.1 ± 0.0 13.5 ± 0.3* 4.3 0.7
Mean 7.6 ± 1.8 12.8 ± 1.5 8.2 ± 1.9* 5.2 ± 0.4 0.6 ± 0.3
Reserpine was administered at 10 mg/kg for 2 hr. The dose of clorgyline (2.5 mg/kg, 18 hr) used produces a selective
inhibition of MAO type A in brain (15, 16). Data are the mean ± SEM with three or four mice per group.
*P < 0.001 compared to reserpine alone (values in column B). Individual experiments were compared by a two-tailed
Student t test and the pooled means by a paired t test.
reductase at 16 ,ug/ml, the rate of color formation (rate of
formation of 5-thio-2-nitrobenzoate) was monitored between
1 and 4 min at 412 nm and ambient temperature. A Stasar III
flow-through spectrophotometer (Gilford) was used. Rates
were corrected for the blank rate in the absence of added
tissue extract and compared to a standard curve obtained
with known amounts of GSSG, similarly corrected for the
blank.
Dopamine and its acidic metabolites, 3,4-dihydroxyphen-
ylacetic acid and homovanillic acid, in the acidified homoge-
nates of striatum were measured by HPLC with electrochem-
ical detection (14).
RESULTS
In eight independent experiments with three or four mice per
group, the levels of GSSG were significantly elevated 2 hr
after the administration of reserpine: GSSG in the striatum
rose by 4.3-6.3 AM (mean 5.1 puM, P < 0.001 in each
experiment). The increment in GSSG was 87.8 ± 10.7%
(mean ± SEM) of the basal levels seen in corresponding
control groups. Therefore, mobilization of dopamine by
reserpine is associated with a substantial rise in striatal levels
of GSSG.
Over this time period, the mean level of dopamine in the
striatum fell from 50.9 AM to 1.4 ,uM (n = 6), while the
steady-state levels of the acidic metabolites, 3,4-dihydroxy-
phenylacetic acid and homovanillic acid, doubled (from 4.8
,M to 8.8 AM and from 5.9 to 12.3 ,M, respectively). These
results confirm the expected increase in MAO activity. The
mean rise in GSSG (5.1 ,M) is readily accommodated by the
H202 that would be generated during the observed loss of
dopamine (49.5 AM). It should be noted that the change in
dopamine concentration in the striatum does not take into
account the metabolism of newly synthesized dopamine
during exposure to reserpine.
Table 1 shows the results of experiments in which reser-
pine was administrated with clorgyline, a selective inhibitor
(15, 16) of MAO type A. In each of four experiments,
clorgyline suppressed the rise in GSSG (P < 0.001); the mean
suppression was 88%. The results are consistent with an
inhibition of MAO within dopamine nerve terminals that, in
rodents, contain mainly or exclusively MAO type A (17, 18).
The extensive suppression by clorgyline indicates a relative
lack of participation by MAO type B, such as that present in
glia (19). Clorgyline alone did not affect GSSG (controls, 5.6
0.6 uM, and clorgyline-treated, 5.8 ± 0.1 .tM; n = 3 per
group).
The striatum is relatively enriched with dopamine nerve
terminals, whereas the frontal cortex receives a sparser
innervation by catecholamine (dopamine and norepineph-
rine) terminals (20, 21). A marked differential was seen
between the responses of the striatum and cortex (Table 2).
Whereas the striatum exhibited a significant rise in GSSG
after reserpine, the frontal cortex did not. The mean change
in GSSG in three experiments was +5.0 ± 0.3 ixM in the
striatum and -0.3 ± 0.6 ,uM in the cortex. Therefore, the
response parallels the degree of innervation by catechola-
mine terminals.
DISCUSSION
The current technology, as applied to brain, requires that a
very small mass of monoamine nerve terminals, embedded
within a much greater mass of brain tissue, be viewed against
the background of the tissue as a whole. Because GSH is
ubiquitously distributed, the loss in GSH would be difficult to
detect. However, the basal level of GSS0 is quite low and,
therefore, an elevation in GSSG within a small tissue com-
partment can be observed as a significant rise in the average
tissue level ofGSSG. It is probable that the rise in GSSG seen
in the striatum after injection of reserpine is localized mainly
to dopamine nerve terminals. In that event, the results signify
very much higher concentrations of GSSG within dopamine
terminals. It is apparent that the rate of production of H202
evoked by reserpine is sufficient to override cellular mech-
anisms for reducing GSSG.
Reserpine promotes MAO activity in other monoamine-
secreting neurons. It is reasonable to expect that significant
elevations in GSSG also take place in mesolimbic and
mesocortical dopamine terminals, as well as in projections of
central norepinephrine and serotonin neurons. The striatum,




Exp. Control Reserpine in GSSG Control Reserpine in GSSG
1 5.2 ± 0.5 10.7 ± 0.3* 5.5 5.4 ± 0.6 4.1 ± 0.2 -1.3
2 8.5 ± 0.3 13.4 ± 0.2* 4.9 8.3 ± 0.4 9.0 ± 0.2 0.7
3 3.6 ± 0.3 8.2 ± 0.3* 4.6 3.6 ± 0.3 3.4 ± 0.2 -0.2
Mean 5.8 ± 1.4 10.8 ± 1.5* 5.0 ± 0.3 5.8 ± 1.4 5.5 ± 1.8 -0.3 ± 0.6
Reserpine was administered at 10 mg/kg for 2 hr. Data are the mean ± SEM with three or four mice per group.
*P < 0.001 compared to controls. Individual experiments were compared by a two-tailed Student t test and the pooled means
by a paired t test.
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with its relatively dense innervation by monoamine neurons,
provided the means to study GSSG in a selected neuronal
type. The frontal cortex, with its sparser innervation, served
as an essential negative control (Table 2). Improvements in
technology will be required to facilitate the study of mono-
amine neurons in brain regions that are less densely inner-
vated than the striatum.
The observation that reserpine elevates striatal GSSG in
vivo, reported here, is supported by in vitro observations with
isolated nerve terminals. When striatal synaptosomes are
incubated with reserpine and L-dopa (0.04-1.0 mM), the
levels of GSSG rise significantly and the rise is blocked by
clorgyline (22, 23). The addition of L-dopa, an immediate
precursor of dopamine, is required in vitro because endoge-
nous dopamine is lost during the preparation of synapto-
somes. In vivo, however, the high intracellular pool of
dopamine, which has been estimated at 50 mM within striatal
nerve terminals (24), along with continued biosynthesis of
fresh dopamine, provides adequate substrate for neuronal
MAO.
A therapeutic trial of "antioxidants" to slow the progres-
sion of Parkinson disease (25) is predicated, in part, on the
theory that an oxidant stress derived from the turnover of
fleurotransmitter by MAO contributes to the loss of dopa-
mine neurons (26). The current data show that accelerated
presynaptic metabolism of dopamine can lead to a detectable
alteration in the redox status of dopamine terminals. To the
best of our knowledge, a direct demonstration of an oxidant
stress under these circumstances has not been achieved
previously.
In other biological systems, enhanced production of H202
is associated with cell damage and destruction. Examples are
phagocytosis (27) and cell or organ-specific redox-cycling
toxins, such as paraquat, doxorubicin, and alloxan. Within
the nervous system, 6-hydroxydopamine and 6-amino-
dopamine are examples of redox-cycling toxins that selec-
tively destroy catecholamine neurons (28). However, in each
of these examples, the production of H202 is undoubtedly
more vigorous than that evoked within dopamine nerve
terminals by reserpine and, moreover, strong evidence exists
for contributory roles by other species, which include hypo-
chlorous acid, reactive quinones, superoxide, and the hy-
droxyl radical. Increased production of H202 evoked by
reserpine does not, by itself, evoke a rapid neuronal destruc-
tion, such as that seen with 6-hydroxydopamine. Nonethe-
less, a milder oxidative stress that can persist for years in
nigrostriatal neurons in Parkinson disease (namely, evidence
at autopsy for increased production of deaminated metabo-
lites) would be expected to evoke biologic sequelae.
We suggest that accelerated turnover of dopamine in
Parkinson disease can affect the vitality ofdopamine neurons
and contribute to variations or abnormalities in dopaminergic
neurotransmission, particularly during long-range therapy
with L-dopa. At the far end of a spectrum of possible sequelae,
a persistent oxidative stress, coupled to significant local loss
of GSH, may promote a faster than normal rate of neuronal
senescence. This possibility remains to be explored. Alter-
natively, elevated GSSG can affect the properties of sulfhy-
dryl-dependent enzymes and structural proteins by the for-
mation of mixed disulfides, and it can also serve as a "third
messenger" to alter enzymatic systems or promote a variety
of cellular changes (29-31).
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